Top Markets
#1 QuantixAI QuantixAI +102.94%
#2 MetaDAO MetaDAO +28.44%
#3 龙虾 (Lobster) 龙虾 (Lobster) +27.94%
#4 Rain Rain +23.22%
#5 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +19.58%
#6 Bedrock Bedrock +18.45%
#7 Pons Pons +18.33%
#8 Prom Prom +15.79%
#9 Humanity Humanity +14.45%
#10 Stacks Stacks +11.76%
Coin of the day
QuantixAI QuantixAI
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCL
Classifica tra le azioni #20197
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company... Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Prezzo delle azioni
$10.25
Ultima sincronizzazione: 2024-02-22
Capitalizzazione di mercato
$137.83M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
CN
Scambia Gracell Biotechnologies Inc. (GRCL)

Categoria

Healthcare
Il prezzo GRCL con la capitalizzazione del mercato della B
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.
GRCL
$10.25
Capitalizzazione di mercato di Gracell Biotechnologies Inc.(GRCL)
Capitalizzazione di mercato: $137.83M
A partire dal August 2026, Gracell Biotechnologies Inc. ha una capitalizzazione di mercato pari a $137.83M. Questo rende Gracell Biotechnologies Inc. la 20197th azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Gracell Biotechnologies Inc. dal 2021 al 2026
GRCL in paragone con la classifica dei più popolari stocks
Il prezzo per GRCL Attivo B Capitalizzazione del mercato a B Risultati
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.
$383,178 $137.83M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.152T +3,738,226.07%
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.
$337,408 $137.83M
Apple Inc. Apple Inc.
AAPL
$4.537T +3,291,681.73%
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.
$310,007 $137.83M
Alphabet Inc. Alphabet Inc.
GOOG
$4.169T +3,024,354.90%
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.
$270,873 $137.83M
Microsoft Corporation Microsoft Corporation
MSFT
$3.642T +2,642,564.22%
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.
$208,579 $137.83M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.805T +2,034,819.70%